Phase 2 study of Carboplatin / Nab-paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with malignant pleural efussion
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2016
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary) ; Carboplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 16 Jun 2016 Planned End Date changed from 31 Jul 2017 to 31 Mar 2019.
- 17 Apr 2014 Status changed from planning to recruiting as reported by University Hospital Medical Information Network - Japan.
- 17 Apr 2014 Planned End Date changed to 31 Jul 2017 as reported by University Hospital Medical Information Network - Japan.